CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, inflammation, cardiovascular, and metabolic disease. Our premier Translational Platforms help our clients accelerate their new drug development programs. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services. We are a global company with facilities across the world in the United States, United Kingdom, China, and Taiwan.
As a comprehensive solution provider, CrownBio helps reveal the best clinical possibilities with our proprietary HuPrime®, HuKemia®, HuBase™, HuMark™, HuTrial™, and HuSignature™ platforms enabling the rapid translation of a lead compound into a successful clinical candidate. CrownBio's cutting-edge, proprietary, Translational Technology Platforms provide robust and scientifically sound end-to-end solutions for preclinical drug development.
Content from CrownBio
Explore CrownBio's virtual American Diabetes Association 2020 event to catch up with the latest preclinical research on diabetes, NAFLD/NASH, obesity, cardiovascular and renal diseases.
Dr. Thomas Scullion discusses how to leverage NHP exploratory toxicology studies to guide and explore lead optimization, dosing paradigms, and future GLP studies.
Fred Beasley, PhD discusses how to select the most appropriate animal models for your preclinical obesity studies.
Leigh Goedeke, PhD reviews spontaneous nonhuman primate (NHP) models of NAFLD and metabolic syndrome as a more clinically-relevant preclinical study platform.
Andrew Puca, PhD discusses techniques for optimizing preclinical diabetes research in spontaneously diabetic NHPs, with a focus on stress free assessments of glucose measurement and response using continuous glucose monitoring and the banana tolerance test.